Patterns of hormonal changes in hypophysitis by immune checkpoint inhibitor
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events, including endocrine dysfunctions, which can have serious consequences on patient health and quality of life. The clinical course and characteristics of immune-related hypophysitis (irH) are not well established. This study aimed to analyze the clinical course and characteristics of irH. Methods: This single-center, retrospective study analyzed data from electronic medical records of Asan Medical Center, spanning January 2017 through June 2021. It included adult patients with solid tumors who underwent thyroid and adrenal function tests, along with gonadotropin and/or growth hormone evaluations, following the initiation of ICI treatment within the same period. The study explored the clinical characteristics of ICI-treated patients with and without irH, the incidence of irH, the time to irH onset, and the associated hormonal changes. Results: Twenty-one patients were included in this analysis. Clinical characteristics did not differ significantly between the irH (n = 13) and non-irH (n = 8) groups. Deficiency rates in the irH group were 23.1% for thyroid-stimulating hormone (n = 3), 76.9% for adrenocorticotropic hormone (n = 10), 61.5% for gonadotropin (n = 8), and 15.4% for growth hormone (n = 2). The overall incidence was 0.9 per person-year, with 6-month and 1-year cumulative incidences of 38.8% and 57.1%, respectively. The median time from ICI initiation to irH diagnosis was 7.7 months. Time to levothyroxine replacement was shorter in the irH group. Conclusions: The findings provide evidence that could facilitate the prediction of ICI-induced irH based on clinical course and characteristics.
Abstract
Background/Aims: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events, including endocrine dysfunctions, which can have serious consequences on patient health and quality of life. The clinical course and characteristics of immune-related hypophysitis (irH) are not well established. This study aimed to analyze the clinical course and characteristics of irH. Methods: This single-center, retrospective study analyzed data from electronic medical records of Asan Medical Center, spanning January 2017 through June 2021. It included adult patients with solid tumors who underwent thyroid and adrenal function tests, along with gonadotropin and/or growth hormone evaluations, following the initiation of ICI treatment within the same period. The study explored the clinical characteristics of ICI-treated patients with and without irH, the incidence of irH, the time to irH onset, and the associated hormonal changes. Results: Twenty-one patients were included in this analysis. Clinical characteristics did not differ significantly between the irH (n = 13) and non-irH (n = 8) groups. Deficiency rates in the irH group were 23.1% for thyroid-stimulating hormone (n = 3), 76.9% for adrenocorticotropic hormone (n = 10), 61.5% for gonadotropin (n = 8), and 15.4% for growth hormone (n = 2). The overall incidence was 0.9 per person-year, with 6-month and 1-year cumulative incidences of 38.8% and 57.1%, respectively. The median time from ICI initiation to irH diagnosis was 7.7 months. Time to levothyroxine replacement was shorter in the irH group. Conclusions: The findings provide evidence that could facilitate the prediction of ICI-induced irH based on clinical course and characteristics.
참고문헌 (36)
- Dine J, "Immune checkpoint inhibitors : an innovation in immunotherapy for the treatment and management of patients with cancer", Asia Pac J Oncol Nurs, 4, pp.127~135 (2017)
- Haslam A, "Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs", JAMA Netw Open, 3, pp.e200423~ (2020)
- Schneider BJ, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : ASCO guideline update", J Clin Oncol, 39, pp.4073~4126 (2021)
- Byun DJ, "Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies", Nat Rev Endocrinol, 13, pp.195~207 (2017)
- Iwama S, "Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody", Sci Transl Med, 6, pp.230ra45~ (2014)
- Paschou SA, "How we treat endocrine complications of immune checkpoint inhibitors", ESMO Open, 6, pp.100011~ (2021)
- Ryder M, "Endocrine-related adverse events following ipilimumab in patients with advanced melanoma : a comprehensive retrospective review from a single institution", Endocr Relat Cancer, 21, pp.371~381 (2014)
- Kwon H, "Immune checkpoint inhibitors and endocrine disorders : a position statement from the Korean Endocrine Society", Endocrinol Metab(Seoul), 37, pp.839~850 (2022)
- Mizukoshi T, "Immune checkpoint inhibitor-related hypophysitis", Best Pract Res Clin Endocrinol Metab, 36, pp.101668~ (2022)
- Faje AT, "Ipilimumab-induced hypophysitis : a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma", J Clin Endocrinol Metab, 99, pp.4078~4085 (2014)
- Lam T, "Ipilimumab-induced hypophysitis in melanoma patients : an Australian case series", Intern Med J, 45, pp.1066~1073 (2015)
- Snyders T, "Ipilimumab-induced hypophysitis, a single academic center experience", Pituitary, 22, pp.488~496 (2019)
- Albarel F, "Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma", Eur J Endocrinol, 172, pp.195~204 (2015)
- González-Rodríguez E, "Immune checkpoint inhibitors : review and management of endocrine adverse events", Oncologist, 21, pp.804~816 (2016)
- Barroso-Sousa R, "Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens : a systematic review and meta-analysis", JAMA Oncol, 4, pp.173~182 (2018)
- Cho YK, "Association between serum gamma-glutamyltransferase and the progression of coronary artery calcification", Atherosclerosis, 243, pp.300~306 (2015)
- Rhee EJ, "2018 Guidelines for the management of dyslipidemia", Korean J Intern Med, 34, pp.723~771 (2019)
- Fleseriu M, "Hormonal replacement in hypopituitarism in adults: An Endocrine Society Clinical Practice Guideline", J Clin Endocrinol Metab, 101, pp.3888~3921 (2016)
- Jessel S, "Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function", Front Oncol, 12, pp.836859~ (2022)
- Briet C, "Expert opinion on pituitary complications in immunotherapy", Ann Endocrinol(Paris), 79, pp.562~568 (2018)
- Chen P, "Progress and challenges of immune checkpoint inhibitor-induced hypophysitis", J Clin Med, 12, pp.3468~ (2023)
- Labadzhyan A, "Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy : a prospective study", J Clin Endocrinol Metab, 107, pp.1976~1982 (2022)
- Persani L, "2018 European Thyroid Association(ETA)guidelines on the diagnosis and management of central hypothyroidism", Eur Thyroid J, 7, pp.225~237 (2018)
- Hartman ML, "Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?", J Clin Endocrinol Metab, 87, pp.477~485 (2002)
- Biller BM, "Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency", J Clin Endocrinol Metab, 87, pp.2067~2079 (2002)
- Caturegli P, "Autoimmune hypophysitis", Endocr Rev, 26, pp.599~614 (2005)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Corsello SM, "Endocrine side effects induced by immune checkpoint inhibitors", J Clin Endocrinol Metab, 98, pp.1361~1375 (2013)
- Faje A, "Immunotherapy and hypophysitis : clinical presentation, treatment, and biologic insights", Pituitary, 19, pp.82~92 (2016)
- Inaba H, "Endocrine dysfunctions during treatment of immune-checkpoint inhibitors", Trend Immunother, 4, pp.18~26 (2020)
- Caturegli P, "Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4blockade : insights into pathogenesis from an autopsy series", Am J Pathol, 186, pp.3225~3235 (2016)
- Kassi E, "Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma", Cancer Med, 8, pp.6585~6594 (2019)
- Kanie K, "Mechanistic insights into immune checkpoint inhibitor-related hypophysitis : a form of paraneoplastic syndrome", Cancer Immunol Immunother, 70, pp.3669~3677 (2021)
- Tan MH, "Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients : a scoping review of case reports", Clin Diabetes Endocrinol, 5, pp.1~ (2019)
- Stelmachowska-Banaś M, "Management of endocrine immune-related adverse events of immune checkpoint inhibitors : an updated review", Endocr Connect, 9, pp.R207~R228 (2020)
- Lupi I, "Clinical heterogeneity of hypophysitis secondary to PD-1", PD-L1 blockade : insights from four cases, 2019, pp.2019, 19~0102